Accuray Incorporated Company Profile (NASDAQ:ARAY)

About Accuray Incorporated (NASDAQ:ARAY)

Accuray Incorporated logoAccuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ARAY
  • CUSIP: 00439710
  • Web: www.accuray.com
Capitalization:
  • Market Cap: $360.15 million
  • Outstanding Shares: 83,179,000
Average Prices:
  • 50 Day Moving Avg: $4.25
  • 200 Day Moving Avg: $4.33
  • 52 Week Range: $3.60 - $6.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -86.00
  • P/E Growth: 0.08
Sales & Book Value:
  • Annual Revenue: $383.41 million
  • Price / Sales: 0.93
  • Book Value: $0.56 per share
  • Price / Book: 7.68
Profitability:
  • EBITDA: $640,996.00
  • Net Margins: -7.71%
  • Return on Equity: -61.62%
  • Return on Assets: -7.12%
Debt:
  • Debt-to-Equity Ratio: 1.11%
  • Current Ratio: 1.09%
  • Quick Ratio: 0.72%
Misc:
  • Average Volume: 560,692 shs.
  • Beta: 1.21
  • Short Ratio: 11.88
 

Frequently Asked Questions for Accuray Incorporated (NASDAQ:ARAY)

What is Accuray Incorporated's stock symbol?

Accuray Incorporated trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray Incorporated's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) posted its earnings results on Tuesday, August, 22nd. The company reported ($0.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.05. The business had revenue of $112.09 million for the quarter, compared to analyst estimates of $112 million. Accuray Incorporated had a negative return on equity of 61.62% and a negative net margin of 7.71%. The company's quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) earnings per share. View Accuray Incorporated's Earnings History.

When will Accuray Incorporated make its next earnings announcement?

Accuray Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Accuray Incorporated.

Where is Accuray Incorporated's stock going? Where will Accuray Incorporated's stock price be in 2017?

5 brokers have issued twelve-month price objectives for Accuray Incorporated's shares. Their predictions range from $5.00 to $7.00. On average, they anticipate Accuray Incorporated's share price to reach $6.00 in the next twelve months. View Analyst Ratings for Accuray Incorporated.

What are analysts saying about Accuray Incorporated stock?

Here are some recent quotes from research analysts about Accuray Incorporated stock:

  • 1. According to Zacks Investment Research, "Over the past year, Accuray has underperformed the broader industry with respect to price. Accuray reported wider-than-expected loss in the fourth quarter of fiscal 2017, primarily due to lackluster performance in the service revenue segment. The company issued solid fiscal 2018 guidance. Of the recent developments, orders for the latest Radixact System, solid revenue performance in APAC and Japanese regulatory approval for Radixact are key positives in our view. However, unfavorable product mix, declining service revenues, sluggish macro economic conditions and pricing headwinds are major concerns. Notably, China and Europe saw sluggish revenues in the fourth quarter. Accuray’s significant international presence helps broaden its customer base. However, fluctuations in currency exchange rates, particularly with a strong dollar, will continue to adversely impact the company’s backlog and top line." (9/19/2017)
  • 2. BTIG Research analysts commented, "Results: In-Line Revenue with Soft Net Orders; Neutral ARAY’s results the past few years seem to reflect a company hampered by its positioning with low market share, missed guidance, delays by the Chinese government and a tough capital structure that is trying to do all that it can to reaccelerate growth. Our concern is that continued single digit growth with lumpy orders and some quarterly revenue misses just doesn’t excite investors and we are not sure what will accelerate growth meaningfully. We applaud new product innovation and focus on consistent results. With guidance reset earlier in the year, ARAY reported in-line rev but the conversion from orders has taken longer than expected with some geographic softness. ARAY is attempting to increase growth through multiple new products such as Radixact, OnRad, Precision Treatment Planning, and iDMS Data Management. We believe this may help but at the end of the day past execution keeps us at Neutral. FY18 guidance calls for revenue of $390M – $400M (2% – 4%) and gross order growth of 5%. Both seem reasonable but also not layups. We will continue to watch for more consistency and stronger growth that would bring investors back into the story." (8/24/2017)
  • 3. Aegis analysts commented, "The company has been successful in shifting gears to the smaller vault centers, re-positioning TomoTherapy as a work horse machine. Accuray has moved outside of the niche high-end large academic centers into the broader single- and dual-vault centers, with single- and dual-vault centers now accounting for 50% of new TomoTherapy orders (up from 0% in 2012).He added, "Radixact, the next-generation TomoTherapy platform, was approved for 510k in June (CE Mark in Aug) and brings ARAY up to par with Varian's TrueBeam and Elekta's Axesse machines. Radixact adds higher output dosing along with integrated treatment planning (Precision') and data management (iDMS') systems that will increase the ease and speed of systems, and should have its full launch in time for ARAYs first major replacement cycle. The reliability issues previously associated with TomoTherapy are now behind them, and Tomo is consistantly ranked #1 in overall system performance by ServiceTrak." (2/6/2017)

Who are some of Accuray Incorporated's key competitors?

Who are Accuray Incorporated's key executives?

Accuray Incorporated's management team includes the folowing people:

  • Louis J. Lavigne Jr., Independent Chairperson of the Board
  • Joshua H. Levine, President, Chief Executive Officer, Director
  • Elizabeth H. Davila, Independent Vice Chairperson of the Board
  • Kevin Waters, Chief Financial Officer, Senior Vice President
  • Alaleh Nouri, Senior Vice President, General Counsel, Corporate Secretary
  • Lionel Hadjadjeba, Senior Vice President, Chief Commercial Officer
  • Andy Kirkpatrick, Senior Vice President - Global Operations
  • Shig Hamamatsu, Vice President, Finance and Chief Accounting Officer, Principal Accounting Officer
  • Jack Goldstein Ph.D., Independent Director
  • Richard R. Pettingill, Independent Director

How do I buy Accuray Incorporated stock?

Shares of Accuray Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accuray Incorporated's stock price today?

One share of Accuray Incorporated stock can currently be purchased for approximately $4.30.


MarketBeat Community Rating for Accuray Incorporated (NASDAQ ARAY)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Accuray Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Accuray Incorporated (NASDAQ:ARAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $6.00 (39.53% upside)
Consensus Price Target History for Accuray Incorporated (NASDAQ:ARAY)
Price Target History for Accuray Incorporated (NASDAQ:ARAY)
Analysts' Ratings History for Accuray Incorporated (NASDAQ:ARAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2017BTIG ResearchReiterated RatingHoldMediumView Rating Details
8/24/2017Royal Bank Of CanadaReiterated RatingHold$5.00LowView Rating Details
8/23/2017Jefferies Group LLCLower Price TargetBuy$7.00 -> $6.00LowView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
12/14/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$8.00 -> $6.00N/AView Rating Details
9/13/2016Cowen and CompanyInitiated CoverageOutperform$9.00N/AView Rating Details
8/18/2016Morgan StanleySet Price TargetHold$8.00N/AView Rating Details
5/22/2016Brean CapitalReiterated RatingBuy$12.00N/AView Rating Details
11/12/2015Citigroup Inc.Initiated CoverageSellN/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Accuray Incorporated (NASDAQ:ARAY)
Earnings by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Earnings History by Quarter for Accuray Incorporated (NASDAQ ARAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017($0.09)N/AView Earnings Details
8/22/20176/30/2017($0.01)($0.06)$112.00 million$112.09 millionViewN/AView Earnings Details
4/27/2017Q3 2017$0.01($0.06)$110.23 million$97.31 millionViewN/AView Earnings Details
1/31/2017Q217($0.09)($0.11)$93.74 million$87.50 millionViewListenView Earnings Details
10/27/2016Q117($0.10)($0.12)$37.34 million$86.50 millionViewListenView Earnings Details
8/17/2016Q316($0.07)($0.09)$98.97 million$95.00 millionViewListenView Earnings Details
4/26/2016Q316($0.06)$0.01$102.79 million$105.30 millionViewListenView Earnings Details
1/28/2016Q216($0.08)($0.08)$101.15 million$108.90 millionViewListenView Earnings Details
10/29/2015Q116($0.14)($0.12)$88.60 million$89.60 millionViewListenView Earnings Details
8/20/2015Q415($0.04)($0.07)$102.41 million$101.80 millionViewListenView Earnings Details
4/30/2015Q315($0.06)($0.04)$102.72 million$97.50 millionViewListenView Earnings Details
1/27/2015Q215($0.08)($0.13)$98.87 million$98.20 millionViewListenView Earnings Details
10/29/2014Q115($0.13)($0.28)$88.90 million$82.40 millionViewListenView Earnings Details
8/21/2014Q414($0.07)($0.13)$92.23 million$102.00 millionViewListenView Earnings Details
4/30/2014Q314($0.16)($0.06)$82.00 million$97.10 millionViewListenView Earnings Details
1/30/2014Q214($0.20)($0.07)$80.20 million$93.60 millionViewListenView Earnings Details
11/7/2013Q114($0.20)($0.21)$79.67 million$76.60 millionViewListenView Earnings Details
8/27/2013Q4 2013($0.20)($0.20)$82.29 million$84.90 millionViewListenView Earnings Details
5/7/2013Q3 2013($0.22)($0.37)$77.97 million$70.55 millionViewListenView Earnings Details
2/6/2013Q2 2013($0.33)($0.30)$74.23 million$77.80 millionViewListenView Earnings Details
11/7/2012Q113($0.22)($0.23)$85.41 million$83.00 millionViewN/AView Earnings Details
9/6/2012Q412($0.12)($0.20)$106.92 million$100.50 millionViewN/AView Earnings Details
5/8/2012($0.14)($0.21)ViewN/AView Earnings Details
11/8/2011($0.29)($0.38)ViewN/AView Earnings Details
9/19/2011$0.02($0.40)ViewN/AView Earnings Details
5/5/2011$0.04($0.02)ViewN/AView Earnings Details
1/27/2011($0.01)$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Accuray Incorporated (NASDAQ:ARAY)
2017 EPS Consensus Estimate: ($0.12)
2018 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171$0.02$0.02$0.02
Q4 20171$0.02$0.02$0.02
Q1 20181($0.04)($0.04)($0.04)
Q2 20181($0.05)($0.05)($0.05)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Accuray Incorporated (NASDAQ:ARAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Accuray Incorporated (NASDAQ:ARAY)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 76.66%
Insider Trades by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Institutional Ownership by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Insider Trades by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Kelly LondyCOOSell99,136$4.24$420,336.64View SEC Filing  
11/9/2015Joshua LevineCEOBuy50,000$7.12$356,000.00View SEC Filing  
2/2/2015Alaleh NouriSVPSell5,164$7.38$38,110.32View SEC Filing  
11/30/2014Alaleh NouriSVPSell268$6.62$1,774.16View SEC Filing  
11/30/2014Kelly LondyEVPSell2,273$6.62$15,047.26View SEC Filing  
11/3/2014Joshua LevineCEOBuy100,000$6.34$634,000.00View SEC Filing  
5/6/2014Joshua LevineCEOBuy50,000$8.15$407,500.00View SEC Filing  
2/4/2014Richard PettingillDirectorBuy9,795$10.33$101,182.35View SEC Filing  
12/4/2013Jack GoldsteinDirectorSell7,000$7.70$53,900.00View SEC Filing  
12/3/2013Elizabeth DavilaDirectorSell8,000$7.74$61,920.00View SEC Filing  
9/4/2013Darren J MillikenSVPSell11,002$6.53$71,843.06View SEC Filing  
3/5/2013Dennis L WingerDirectorBuy20,000$4.30$86,000.00View SEC Filing  
2/13/2013Joshua LevineCEOBuy100,000$4.38$438,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Accuray Incorporated (NASDAQ:ARAY)
Latest Headlines for Accuray Incorporated (NASDAQ:ARAY)
Source:
Loading headlines, please wait.

Social

Chart

Accuray Incorporated (ARAY) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.